Anifrolumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anifrolumab
Monoclonal antibody
Type Whole antibody
Source Human
Target Interferon α/β receptor
Clinical data
Routes of
administration
Intravenous
ATC code none
Identifiers
CAS Number 1326232-46-5
ChemSpider none
Chemical and physical data
Formula C6444H9964N1712O2018S44
Molar mass 145.12 kg/mol

Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.[2]

This drug was developed by MedImmune. A Phase II clinical trial was completed in 2016. Two Phase III trials are planned as of August 2016.[3]

Adverse effects[edit]

The most common adverse effect in the study was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[3]

References[edit]

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2). 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
  3. ^ a b H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).